Cure Today20h
FDA Grants Breakthrough Therapy Designation to Trodelvy for Small Cell Lung Cancer
The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...
Hosted on MSN3d
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...
The American Journal of Managed Care4d
Top 5 NSCLC Content for 2024
Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data ...
Daily5d
Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy
Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell ...
Gilead and Terray link to develop small-molecule therapies
In September 2024, Gilead announced a strategic partnership with Genesis Therapeutics, focusing on AI to discover and develop ...
Contract Pharma6d
Trodelvy Granted FDA Breakthrough Therapy Designation
A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...
Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure
Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...
The Pharma Letter6d
FDA Breakthrough status for Trodelvy in ES-SCLC
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...
Targeted Oncology7d
FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC
The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...
Gilead gets FDA breakthrough therapy status for Trodelvy
Gilead Sciences (NASDAQ:GILD) said it has received FDA Breakthrough Therapy Designation for its antibody-drug conjugate ...
FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...